In Parkinson's, the brainstem neurons that fail first carry heavy mitochondrial DNA damage — and a hint that some fight back
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
Much of Parkinson's research focuses on dopamine neurons and tremor. But some of the disease's most disabling, treatment-resistant symptoms — gait and balance problems, sleep disturbance, cognitive decline, psychosis — track with the loss of a different population: acetylcholine-producing brainstem neurons.
Researchers at the University of Birmingham and Newcastle University carried out the first single-cell mitochondrial DNA analysis of those neurons, using postmortem tissue from people with Parkinson's and healthy controls, in a study published October 7, 2026 in Brain and reported by MedicalXpress.
What damage did they find?
The neurons carried extensive large-scale deletions in their mitochondrial DNA, concentrated in the major arc — a region packed with genes essential for energy production. Damage there strikes directly at a neuron's ability to make ATP, which may help explain why these high-demand cells are so vulnerable.
What was the unexpected protective signal?
The team found evidence of a response involving PINK1, a mitochondrial quality-control gene already famous in Parkinson's genetics. That response was particularly pronounced in people who survived longer after diagnosis — raising the possibility that strengthening the brain's own mitochondrial quality-control could one day help protect these neurons. That is a hypothesis from human tissue patterns, not a demonstrated therapy.
Where the evidence stands
- Established: Mitochondrial DNA damage and impaired energy production are implicated in Parkinson's neurodegeneration, and PINK1 is a core mitochondrial quality-control gene.
- Preliminary: Single-cell sequencing of human postmortem brainstem neurons (Brain, Oct 7, 2026) found extensive mtDNA major-arc deletions and a PINK1-linked response associated with longer survival after diagnosis.
- Absent: Evidence that boosting PINK1 or any quality-control pathway protects these neurons in living patients, or any treatment based on this finding.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.